The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drugfor use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling.本發明係關於NEP抑制劑前藥N-(3-羧基-1-側氧基丙基)-(4S)-對苯基苯甲基)-4-胺基-(2R)-甲基丁酸乙酯或其醫藥上可接受的鹽;或NEP抑制劑N-(3-羧基-1-側氧基丙基)-(4S)-對苯基苯甲基)-4-胺基-(2R)-甲基丁酸或其醫藥上可接受的鹽、前藥,其用於治療、預防特徵在於心房擴大及/或重塑之疾病或延緩其進展;一種治療、預防特徵在於心房擴大及/或重塑之疾病或延緩其進展的方法,其包括給需要該治療之個體(例如人類個體)投與治療有效量或預防有效量之NEP抑制劑或NEP抑制劑前藥,或其醫藥上可接受的鹽、前藥。本發明進一步係關於一種包含NEP抑制劑或NEP抑制劑前藥,或其醫藥上可接受的鹽、前藥的醫藥組合物或商業包裝,其用於治療、預防特徵在於心房擴大及/或重塑之疾病或延緩其進展。
